Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

NCT03447470 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumor

Interventions

DRUG: RXC004
DRUG: Nivolumab

Sponsor

Redx Pharma Ltd